

Rating Rationale

March 17, 2022 | Mumbai

Global Health Care Products

Rating Reaffirmed and Withdrawn

Rating Action

| Total Bank Loan Facilities Rated | Rs.15 Crore | | |
|----------------------------------|--|--|--|
| Long Term Rating | CRISIL BBB-/Stable (Rating Reaffirmed and Withdrawn) | | |

1 crore = 10 million

Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has reaffirmed its rating on the bank facilities of Global Health Care Products (GHCP) and subsequently **withdrawn** the rating at the company's request and on receipt of a no-objection certificate from the bankers. The withdrawal is in line with CRISIL Ratings' policy on withdrawal of bank loan ratings.

Analytical Approach

Out of the total unsecured loan of Rs. 19.15 crores; upto Rs 14.35 crore has been treated as neither debt nor equity as the loan is likely to be retained in the business over the medium term, rest is treated as debt.

Key Rating Drivers & Detailed Description

Strengths:

Extensive experience of the partners: Presence of over 20 years in the FMCG industry has enabled the partners to develop healthy relationships with customers. The firm has been associated with various clients such as Hindustan Unilever Ltd and Colgate Palmolive (India) Ltd and is now a contract manufacturer for GSK.

Above-average financial risk profile: Networth remained strong at Rs 37.68 crore and total outside liabilities to adjusted networth ratio was low at 0.63 time as on March 31, 2021. Debt protection metrics were healthy with interest coverage and net cash accrual to adjusted debt ratios at 7.34 times and 1.16 times, respectively, for fiscal 2021. The financial risk profile should remain above average over the medium term backed by healthy accretion to reserves and no debt-funded capital expenditure (capex).

Weakness:

High customer concentration risk: GHCP manufactures toothpaste for a single customer GSK. Therefore, the firm is susceptible to high customer concentration risk as its performance is directly linked to that of GSK. Further, operating performance mainly operating profitability is linked to contract terms. Any change in the same could adversely affect revenue and profitability for the firm.

Moderate scale of operations: Although on increasing trend, company's scale of operations continues to remain moderate with revenue of Rs. 170.28 crores for the fiscal ended 31st March 2021. Further scalability of the revenue will also depend on ability of the company to increase its capacity along with its ramp up.

Liquidity: Adequate

Bank limit utilisation is low at around 17 percent for the past twelve months ended 31 st January 2021. Cash accruals are expected to be over Rs 7.35-7.85 crores against no term debt obligation over the medium term. In addition, it will be act as cushion to the liquidity of the company. Current ratio is healthy at 3.02 times on March 31, 2021. The promoters are likely to extend support in the form of equity and unsecured loans to meet its working capital requirements and repayment obligations. High cash and bank balance of around Rs. 11 crores as on March 31, 2021. Low gearing and moderate net worth support it's financial flexibility, and provides the financial cushion available in case of any adverse conditions or downturn in the business

Outlook: Stable

CRISIL Ratings believe GHCP's business risk profile will remain stable over the medium term due to the contract with GSK for next four years.

Rating Sensitivity Factors

Upward factors

- Sustained growth in revenues by 30% along with sustenance of operating margin , while maintaining the overall business risk profile including client relationships, leading to higher net cash accruals
- Stable working capital cycle and maintenance of capital structure

Downward factors

- Decline in revenues by over 15% or dip in operating margins leading to lower net cash accruals
- Increase in working capital requirement, larger-than-expected debt funded capex or acquisition, or more-than-expected
 capital withdrawals, weakening the financial risk profile, particularly liquidity.
- Any material changes, including termination or reduction in contracted volume, to key customer contracts

About the Firm

Set up in 1997, GHCP is a partnership concern promoted by Mr Vasudev Baburao Prabhu and his family. The firm manufactures toothpaste and has capacity of 15,000 tonne per annum.

Key Financial Indicators

| As on/for the period ended March 31 | Unit | 2021 | 2020 |
|-------------------------------------|----------|--------|--------|
| Operating income | Rs.Crore | 170.28 | 141.17 |
| Reported profit after tax | Rs.Crore | 7.13 | 7.39 |
| PAT Margins | % | 4.19 | 5.23 |
| Adjusted Debt/Adjusted Networth | Times | 0.16 | 0.08 |
| Interest coverage | Times | 6.79 | 8.38 |

Note on complexity levels of the rated instrument:

CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

| ISIN | Name of instrument | Date of allotment | Coupon rate (%) | Maturity date | Issue size (Rs.Crore) | Complexity level | Rating assigned with outlook |
|------|--|-------------------|-----------------|------------------|-----------------------------|------------------|--|
| NA | Cash Credit | NA | NA | NA | 4.5 | NA | CRISIL BBB-/Stable (Rating Reaffirmed and Withdrawn) |
| NA | Proposed Long Term Bank Loan Facility | NA | NA | NA | 10.5 | NA | CRISIL BBB-/Stable (Rating Reaffirmed and Withdrawn) |

Annexure - Rating History for last 3 Years

| | Current | | 2022 (| (History) | 20 | 21 | 2 | 020 | 2 | 2019 | Start of 2019 | |
|--------------------------|---------|-----------------------|--|-----------|--------|----------|---------------------------|------|--------|----------|------------------------|---------------------|
| Instrument | Туре | Outstanding Amount | Rating | Date | Rating | Date | Rating | Date | Rating | Date | Rating | Rating |
| Fund Based Facilities | LT | 15.0 | CRISIL BBB- /Stable (Rating Reaffirmed and Withdrawn) | | | 29-01-21 | CRISIL BBB- /Stable | | | 09-12-19 | CRISIL BB+/Positive | CRISIL BB/Stable |

All amounts are in Rs.Cr.

Annexure - Details of Bank Lenders & Facilities

| Facility | Amount (Rs.Crore) | Rating |
|---------------------------------------|-------------------|--|
| Cash Credit | 4.5 | CRISIL BBB-/Stable (Rating Reaffirmed and Withdrawn) |
| Proposed Long Term Bank Loan Facility | 10.5 | CRISIL BBB-/Stable (Rating Reaffirmed and Withdrawn) |

Criteria Details

| Links | to re | lated c | riteria |
|-------|-------|---------|---------|
| | | | |

CRISILs Approach to Financial Ratios

Rating criteria for manufaturing and service sector companies

CRISILs Bank Loan Ratings - process, scale and default recognition

CRISILs Bank Loan Ratings

Rating Criteria for Fast Moving Consumer Goods Industry

| Media Relations | Analytical Contacts | Customer Service Helpdesk |
|---|---|--|
| Pankaj Rawat Media Relations CRISIL Limited B: +91 22 3342 3000 pankaj.rawat@crisil.com | Rahul Subrato Kumar Guha Director CRISIL Ratings Limited D:+91 22 4097 8320 rahul.guha@crisil.com | Timings: 10.00 am to 7.00 pm Toll free Number:1800 267 1301 For a copy of Rationales / Rating Reports CRISILratingdesk@crisil.com |
| Hiral Jani Vasani Media Relations CRISIL Limited B: +91 22 3342 3000 hiral.vasani@crisil.com | Jumana Badshah Associate Director CRISIL Ratings Limited D:+91 22 3342 8324 Jumana.Badshah@crisil.com | For Analytical queries: ratingsinvestordesk@crisil.com |
| Rutuja Gaikwad Media Relations CRISIL Limited B: +91 22 3342 3000 Rutuja.Gaikwad@ext-crisil.com | Aashpreet Kaur Giddey Rating Analyst CRISIL Ratings Limited B:+91 22 3342 3000 Aashpreet.Giddey@crisil.com | |

Note for Media:

This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.

About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit www.crisilratings.com

About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

CRISII PRIVACY NOTICE

CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL's privacy policy please visit www.crisil.com.

DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') that is provided by CRISIL Ratings Limited ('CRISIL Ratings'). To avoid doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, 'CRISIL Ratings Parties') guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings

are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

CRISIL Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html